About bioAffinity Technologies
bioAffinity Technologies (NASDAQ:BIAF) is a biomedical company focused on developing and marketing non-invasive diagnostic tests and cancer therapeutics. The company's flagship project, CyPath® Lung, aims to revolutionize early lung cancer detection through a simple sputum test. bioAffinity Technologies is committed to improving patient outcomes by providing accurate, early-stage cancer detection options that can lead to more effective treatment and increased survival rates. Their objective is to extend diagnostic technologies across multiple types of cancer, emphasizing the importance of early detection in cancer care. Through innovative research and strategic partnerships, bioAffinity Technologies strives to make a significant impact in the fight against cancer.
Snapshot
Operations
Products and/or services of bioAffinity Technologies
- CyPath® Lung, a non-invasive test for the early detection of lung cancer using flow cytometry and proprietary bio-marker technology.
- TumorGenesis, a division focused on creating patient-specific cancer environments for more effective drug testing and disease understanding.
- Cancer research partnership programs that collaborate with academic and medical institutions to develop new diagnostic tools and therapies.
bioAffinity Technologies executive team
- Mr. Steven GirgentiFounder & Executive Chairman of the Board
- Ms. Maria Zannes J.D.Founder, President, CEO & Director
- Mr. James Michael Edwards CPA, M.B.A.Chief Financial Officer
- Mr. Xavier T. Reveles M.S.Chief Operating Officer
- Dr. William Bauta Ph.D.Chief Science Officer
- Mr. Timothy P. Zannes J.D.Executive VP, Secretary & General Counsel
- Ms. Julie Anne OvertonDirector of Communications
- Mr. Dallas J. ColemanVice President of sales
- Dr. Gordon Downie M.D., Ph.D.Chief Medical Officer